Retatrutide vs Tirzepatide vs Semaglutide for Research Labs

What this retatrutide vs tirzepatide vs semaglutide page covers

Procurement tickets for incretin-pathway peptides now arrive as a trio more often than as a single SKU. A PI writes “we need the GLP-1 analog, the dual, and the triple,” a student pastes three brand-adjacent nicknames into one cart, and receiving is left to sort Retatrutide (GLP3-Reta) research peptide, Tirzepatide (GLP2-Tirz) research peptide, and Semaglutide (GLP1-Sema) research peptide before any assay starts. This page is the identity and selection document for that order. It is not a ranking of consumer products and it is not a personal-use comparison.

The three sequences sit in one research family only in the loose sense that each was engineered around incretin or glucagon-family receptors. They are not interchangeable reagents. Receptor occupancy, fatty-acid acylation, and the published sponsor programs that used each code (NN9535, LY3298176, LY3437943) are different facts. Collapsing them into “the weight-loss peptides” is how a purchase order buys the wrong molecule for a binding panel.

Nextday Peptides sells Research Use Only materials. Clinical papers cited below describe what sponsor programs investigated in people. Those papers do not authorize administration, dosing, injection, or cycles. If your work is not laboratory research under an institutional SOP, this comparison is the wrong resource.

If you need the use boundary in writing for a purchasing file, read Research Use Only peptides explained. If you need naming hygiene before you write the requisition, read catalog names, CAS, and peptide identifiers. The rest of this page assumes you already know you are buying reagents, not prescriptions.

Receptor targets: GLP-1R, GIPR, and GCGR on one table

Start with receptors, not with headlines. Semaglutide is a selective GLP-1 receptor (GLP-1R) agonist. Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R. Retatrutide is a triple agonist at GLP-1R, GIPR, and the glucagon receptor (GCGR). Those three sentences are the entire pharmacological reason a methods section should name one analog and not “an incretin peptide.”

Developmental codes still matter on COAs and in older papers. Semaglutide appears as NN9535 in discovery and early development writing. Tirzepatide appears as LY3298176. Retatrutide appears as LY3437943. When a protocol, a grant, or a prior notebook line uses the code, match the code on the product page and the lot file — then match the receptor list. A nickname collision at checkout is cheaper to catch than a month of assays on the wrong agonist.

Acylation is the other structural fact buyers mix up. Lau and colleagues described semaglutide as a GLP-1 analog with two residue substitutions relative to native GLP-1 and a C-18 fatty diacid attached at lysine 26, designed to raise albumin affinity and slow clearance in the sponsor’s pharmaceutical program. Tirzepatide and retatrutide are also fatty-acid–modified peptides in the Lilly discovery papers. The side chain is a pharmacokinetics design choice in those publications. It is not a license to treat the dry research cake as interchangeable with an unrelated 10-residue fragment in your freezer.

On this site the storefront titles keep the compound name first: Retatrutide (GLP3-Reta), Tirzepatide (GLP2-Tirz), Semaglutide (GLP1-Sema). Use the compound name in the purchase order. Catalog suffixes help navigation; they are not CAS replacements and they are not unique freezer keys.

This table is an identity aid for laboratory purchasing. It is not a potency ranking, not a clinical comparison for readers, and not a substitution chart. If your method needs a single receptor, a dual agonist is the wrong reference even when the storefront photos look similar.

Semaglutide (NN9535) as a GLP-1R reference compound

Semaglutide (GLP1-Sema) research peptide is the cleanest single-receptor reference in this trio. Labs that already run GLP-1R binding, cAMP accumulation, or internalization assays often start here because the literature stack is the oldest and the structural story is the most tightly specified: Aib8, Arg34, and the C-18 diacid at Lys26, as laid out in the Lau discovery paper.

That structural specificity is why “semaglutide-like” is a dangerous purchase-order phrase. A generic GLP-1 fragment, a liraglutide analog, or a blend that mentions semaglutide in marketing copy is not NN9535. If the protocol cites semaglutide, buy the single-compound page and record the lot against that name. Blends and neighboring incretin SKUs belong on a different line item.

Sponsor programs that investigated semaglutide in people include the SUSTAIN series (type 2 diabetes setting) and the STEP series (overweight and obesity setting). Wilding and colleagues reported STEP 1 in the New England Journal of Medicine in 2021. Those publications describe a drug-development product under clinical protocol. They do not describe your lyophilized research vial, and they do not tell a bench team how to store or dissolve a cake.

When we review incoming questions, the semaglutide mistakes are usually identity mistakes, not “which freezer.” People order the wrong fill, file the COA under a nickname, or park the vial in a box labeled only “GLP.” Fix the label before the assay calendar starts. Purity percentage on an HPLC trace cannot rescue a misnamed tube.

Tirzepatide (LY3298176) as a dual GIPR/GLP-1R reference

Tirzepatide (GLP2-Tirz) research peptide is the dual-agonist reference. Coskun, Sloop, Loghin, and colleagues described LY3298176 in Molecular Metabolism in 2018 as a fatty-acid–modified peptide with dual GIP and GLP-1 receptor activity, characterized in cell systems and in early clinical proof-of-concept work run by the sponsor. That paper is why a methods section can say “dual GIPR/GLP-1R agonist (LY3298176)” and mean one molecule.

A dual agonist is the wrong control if your question is “does this readout require GLP-1R only?” It is the right control if your question is “how does adding GIPR engagement change the same panel we already ran on semaglutide?” Those are different experimental designs. Buyers who treat tirzepatide as “stronger semaglutide” are shopping with a consumer metaphor. Write the receptor hypothesis first, then pick the SKU.

Frias and colleagues reported SURPASS-2 in 2021, a sponsor phase 3 comparison of tirzepatide versus semaglutide in adults with type 2 diabetes. SURPASS is the diabetes-program name; SURMOUNT is the obesity-program name. Both names show up in literature searches next to LY3298176. Cite them as published clinical context. Do not copy a trial arm into a personal protocol, and do not treat a research vial as the marketed drug product used in those studies.

Documentation discipline is identical to semaglutide: lot, COA, sequence or identity method, and a freezer location that does not say “the other GLP.” If your group already holds semaglutide, add tirzepatide as a second box, not as a second vial dropped into the same bag. Shared bags are how dual and single agonists swap identity at 7 a.m.

Retatrutide (LY3437943) as a triple GLP-1R/GIPR/GCGR reference

Retatrutide (GLP3-Reta) research peptide is the triple-agonist reference. Coskun and colleagues described LY3437943 in Cell Metabolism in 2022 as a peptide agonist at GCGR, GIPR, and GLP-1R, with in-vitro signaling, mouse pharmacology, and a sponsor phase 1 single-ascending-dose study. Jastreboff and colleagues then reported a sponsor phase 2 obesity study in the New England Journal of Medicine in 2023. Lilly’s later phase 3 program uses the TRIUMPH name. Those are the published identifiers. They are not a storefront efficacy claim and they are not a reason to skip a COA.

Adding GCGR to the pair already present on tirzepatide is the scientific reason a lab opens a third SKU. Glucagon-receptor engagement is a different pharmacological axis. If your assay cannot distinguish GCGR contribution, a triple agonist may confound a dual-agonist story rather than complete it. Some groups buy retatrutide only after the GLP-1R and dual panels are stable. Others start with the triple because the grant already named LY3437943. Both are coherent. “Buy all three because the internet ranked them” is not.

We see the same receiving failures on retatrutide that we see on the other two: a lot string that never reaches the freezer log, a cake that sat in a mailroom, and a reconstituted leftover (prepared under an undocumented method) parked next to sealed dry stock. Physical handling belongs on retatrutide storage. Identity belongs here. Do not let a storage SOP substitute for a receptor table.

Catalog neighbors such as mazdutide, survodutide, and cagrilintide are not retatrutide. Dual glucagon/GLP-1 designs and amylin-pathway analogs answer different questions. If the protocol says LY3437943, do not substitute a neighbor because the product photo also shows a lyophilized cake.

Neutral sponsor-trial context: STEP, SUSTAIN, SURPASS, SURMOUNT, TRIUMPH

Literature searches for these three names return clinical trial brands before they return HPLC methods. That is expected. The molecules were developed as pharmaceutical candidates. A research-catalog buyer still needs to know which program belongs to which code so a citation in a grant or a journal club does not drag the wrong vial into the cart.

Semaglutide’s sponsor (Novo Nordisk) published the SUSTAIN program in type 2 diabetes settings and the STEP program in overweight and obesity settings. Wilding 2021 (STEP 1; PMID 33567185) is the paper most purchasing files actually attach when someone asks “which trial is the obesity one?” SUSTAIN-6 and related cardiovascular-outcome work sit in the same molecule’s clinical dossier. None of those protocols is a laboratory reconstitution method.

Tirzepatide’s sponsor (Eli Lilly) published SURPASS in type 2 diabetes settings and SURMOUNT in obesity settings. Frias 2021 (SURPASS-2; PMID 34170647) is the head-to-head versus semaglutide that people paste into Slack. It compares two investigational or approved drug presentations in a clinical trial. It does not rank two research vials on a storefront, and it does not tell you which SKU to stock for a receptor screen.

Retatrutide’s sponsor (Eli Lilly) published the Jastreboff 2023 phase 2 obesity study (PMID 37366315) and has used TRIUMPH as the phase 3 program name. Coskun 2022 (PMID 35985340) is the discovery-to-early-clinical paper for LY3437943. Treat TRIUMPH and Jastreboff as name-to-molecule maps. Do not treat outcome tables as instructions for a person, and do not transcribe clinical dose arms onto a research purchase order.

When a student asks “which one won?”, the honest laboratory answer is: won at what receptor, in what assay, against what control, on which lot? Sponsor endpoint tables are not your plate reader. If you need published human context for a background section, cite the paper. If you need a reagent, cite the sequence, the code, and the COA.

• SUSTAIN and STEP identify semaglutide (NN9535) in sponsor diabetes and obesity programs
• SURPASS and SURMOUNT identify tirzepatide (LY3298176) in sponsor diabetes and obesity programs
• Jastreboff 2023 and the TRIUMPH name identify retatrutide (LY3437943) in sponsor development
• Clinical endpoints are not laboratory acceptance criteria and not personal-use guidance
• A research vial is not the drug product used in those trials

How laboratories pick a reference compound

The groups that waste the least money start from the method, not from a ranking article. Write one sentence: “This assay needs a selective GLP-1R agonist,” or “This panel compares GLP-1R-only versus GIPR/GLP-1R dual engagement,” or “This project requires the published triple agonist LY3437943.” That sentence picks the SKU. Everything else is documentation and logistics.

Match the analog the paper actually used. If the methods cite semaglutide, do not silently substitute tirzepatide because it is “in the same class.” If the grant named retatrutide, do not ship semaglutide as a cheaper proxy. Receptor pharmacology is the experimental variable. Substituting the variable and keeping the name is not thrift; it is a different study.

Then look at paperwork. Pull the lot COA from the COA Library or the batch PDF on the order. Confirm the name on the vial, the fill, and the identity method. Our HPLC purity article covers how to read a percentage without turning it into a clinical claim. A 99% trace on the wrong sequence is still the wrong sequence.

Panel design is a separate decision from single-SKU design. Some labs buy all three because they are mapping selectivity across the incretin/glucagon set. That is a coherent panel: semaglutide as the GLP-1R pole, tirzepatide as the dual, retatrutide as the triple. Other labs buy one analog and a vehicle control. Both designs fail when the three vials share one unlabeled bag or one shared reconstituted stock.

Practical constraints still count. Fill size, budget, freezer space, and the receiving calendar are real. They do not outrank identity. If you can only fund one vial this quarter, fund the analog the signed method names. Add the others when the method, not a forum thread, requires them. Browse the full catalog only after that sentence is written.

We also ask buyers to record why the SKU was chosen. A one-line notebook note — “LY3437943 because the binding panel includes GCGR; lot …; COA filed …” — saves the next student from re-litigating the purchase. Selection without a written reason becomes folklore by the second staff turnover.

• Write the receptor hypothesis before you open the cart
• Match developmental code and compound name to the protocol, not to a nickname
• File the COA and lot before the vial enters a shared study freezer
• Treat a three-SKU panel as three identities, not as one “GLP box”
• Do not substitute across receptors to save a line item

Lot paperwork, COAs, and freezer identity for a three-SKU panel

A comparison on paper dies in the freezer if the labels do. Assign each analog its own box or rack slot. Write compound, developmental code, lot, and date received on a frost-rated tag. Photograph the manufacturer label at intake. If print lifts, the photo is the only way to reconstruct which cake was which.

File PDFs with the lot string in the file name, not with the student’s preferred nickname. “reta-final.pdf” next to “sema-new.pdf” is how audits stall. The how to read a COA page is the reading guide; this page is the reason you keep three files, not one.

Purchase orders should list the compound name first, then the catalog suffix, then the fill, then “single-compound SKU, not blend.” That one clause prevents a well-meaning purchaser from grabbing a combination product because the title mentioned an incretin nickname. If the protocol needs the single sequence, buy the single page.

When a second lot arrives, do not assume the new COA’s identity line is a carbon copy of last quarter’s. Process changes happen. Read the new file. Copy the new lot into the freezer log instead of inheriting last year’s note. Cross-lot comparisons are only valid when both lots are actually the named analog.

Lyophilized form, shipping, and why the three cakes still are not the same

All three research SKUs typically ship as lyophilized solids. That shared form factor is a logistics choice: dry cakes travel and sit better than ambient aqueous stocks. It is not evidence that the sequences share stability, solubility, or assay behavior. Follow each lot’s storage line. Generic “peptide freezer” folklore is how groups invent one SOP for three molecules and then argue about a chromatogram.

Nextday Peptides fulfills from U.S. warehouses in Florida, North Carolina, and California. Same-day processing targets orders placed before 3:30 PM Eastern, Monday–Saturday, after payment clears — details live in the shipping and delivery policy. Transit is not a validated pharmaceutical cold chain for every SKU. Plan receiving so each vial moves into labeled lab storage promptly. Distance from a warehouse is not a reason to skip the lot match.

If you are buying the panel in one carton, ask receiving to open the carton as three identities. Confirm each vial against the packing list before any freezer placement. A single carton is a shipping convenience. It is not permission to inventory the contents as one item.

Solution prep, when the method requires it, is institutional work. We do not publish consumer mixing guides or dose calculators. For retatrutide assay-standard arithmetic framed as laboratory prep, see retatrutide reconstitution. Keep working solutions physically separate from dry stock, and never park three reconstituted analogs in one unlabeled rack.

Related catalog peptides that are not this comparison

Once a lab can name the three receptors, neighboring SKUs become easier to keep out of the cart. Mazdutide and survodutide are glucagon-pathway designs with their own codes and literature. Cagrilintide and the cagrilintide–semaglutide blend are amylin-pathway and combination products. A blend is not a substitute for a single-compound reference, and a neighbor is not “close enough” for a methods citation that named LY3437943.

The same warning applies inside this trio. Do not treat retatrutide as a drop-in for tirzepatide because both lists include GIPR and GLP-1R. The glucagon receptor is not a rounding error. Conversely, do not treat semaglutide as a cheaper retatrutide. You would be buying a different pharmacological tool and calling it a discount.

If your project is really “learn the incretin catalog,” start with the identifier article and a written scope, then add SKUs. Catalog tourism — adding every nickname that appears in a review figure — produces a freezer that nobody can audit. Selection is a quality practice, not a shopping hobby.

Purity evaluation still sits downstream of identity. After you know which analog you hold, use how laboratories evaluate peptide purity for the analytical conversation. Comparing HPLC percentages across three different sequences without naming the sequences is numerology.

Writing the purchase order so the comparison survives receiving

A good requisition for this trio is boring on purpose. Three lines, three slugs, three fills, three “match lot to COA” notes, and one sentence that states whether the order is a selectivity panel or three separate projects that happen to ship together. Purchasing agents should not have to infer intent from a Slack screenshot.

Institutional addresses, not residences, belong on the ship-to. This catalog is Research Use Only. “Near me” retail pickup and pharmacy substitution are not part of fulfillment — see retatrutide near me if someone on the team is still searching that phrase. We ship to supported U.S. laboratory and institutional addresses from the warehouse network above.

Payment must clear before the 3:30 PM Eastern cutoff counts. That is a processing fact, not a quality fact, but it is the difference between a Friday ship and a Monday ship. Coordinate the payment method on payments, refunds, and returns with someone who can receive the box. A perfectly specified trio that sits in a loading dock over a holiday weekend is still a receiving failure.

If a package arrives damaged or the packing list does not match the three SKUs you ordered, photograph everything and contact orders@nextdaypeptides.com within the window in the returns policy. Do not assign lots to studies until the mismatch is cleared. Quarantine is cheaper than a confounding identity error.

Research Use Only: what this comparison is not

Nextday Peptides sells Research Use Only material not for human or veterinary use. This article compares three research-catalog peptides so a laboratory can pick and document the right analog. It does not recommend a product for weight loss, diabetes, anti-aging, or any personal outcome. It does not provide dosing, injection technique, reconstitution “for your dose,” or cycle length.

When we cite STEP, SUSTAIN, SURPASS, SURMOUNT, TRIUMPH, or Jastreboff 2023, we are identifying which molecule a sponsor studied. We are not inviting readers to recreate those protocols. A published clinical paper is not a standing order for a research vial, and a research vial is not a substitute for an approved drug product.

If a purchasing desk needs a one-line use restriction to paste into a vendor file, use this: materials are supplied for laboratory research only; they are not drugs, not supplements, and not for administration to people or animals. Completing a checkout does not change that restriction.

Bottom line for lab buyers comparing the three analogs

Name the receptor set first. Semaglutide is the GLP-1R reference (NN9535, C-18 diacid). Tirzepatide is the GIPR plus GLP-1R reference (LY3298176). Retatrutide is the GLP-1R plus GIPR plus GCGR reference (LY3437943). Sponsor-trial brands tell you which dossier a journalist is quoting. They do not pick your reagent.

Then bind each vial to a lot file, a freezer location, and a written reason for the SKU. That is the entire quality system a comparison article can honestly offer. Storage, reconstitution, and purity reading have their own pages. This page is the identity fork in the road.

If you take only one operational upgrade from this comparison, stop ordering “the GLP peptide” as a single mental object. Three codes, three receptor lists, three boxes. The assays get simpler once the freezer does.